請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65501
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉振軒 | |
dc.contributor.author | Ya-Chu Ting | en |
dc.contributor.author | 丁雅珠 | zh_TW |
dc.date.accessioned | 2021-06-16T23:46:52Z | - |
dc.date.available | 2015-07-27 | |
dc.date.copyright | 2012-07-27 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-07-23 | |
dc.identifier.citation | 1.Abd El‐Rehim DM, Pinder SE, Paish CE, Bell J, Blamey R, Robertson JFR, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203: 661-671, 2004.
2.Alenza M, Pena L, Castillo N, Nieto A. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract 41: 287-291, 2000. 3.Alenza P, Rutteman G, Kuipers-Dijkshoorn N, Pena L, Montoya A, Misdorp W, Cornelisse C. flow cytometry of canine mammary tumours: the relationship of ploidy and S-phase fraction to clinical and histological features. Res Vet Sci 58: 238-243, 1995. 4.Au N, Gown A, Cheang M, Huntsman D, Yorida E, Elliott W, Flint J, English J, Gilks C, Grimes H. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohisto M M 12: 240, 2004. 5.Bacha Jr WJ, Bacha LM. Color atlas of veterinary histology. Wiley-Blackwell, 2011. 6.Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25: 1054, 2001. 7.Barnard NJ, Hall P, Lemoine N, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol 152: 287-295, 1987. 8.Brodey R, Goldschmidt M, Roszel J. Canine mammary gland neoplasms. J Am Anim Hosp Assoc 19: 61-90, 1983. 9.Bureau C, Hanoun N, Torrisani J, Vinel JP, Buscail L, Cordelier P. Expression and function of Kruppel like-factors (KLF) in carcinogenesis. Curr genomics 10: 353, 2009. 10.Cassali G, Gobbi H, Malm C, Schmitt F. Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: comparative features with human tumours. Cytopathology 18: 191-196, 2007. 11.Chang J, Ormerod M, Powles T, Allred D, Ashley S, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89: 2145-2152, 2000. 12.Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc 227: 1625-1629, 2005. 13.Charpin C, Andrac L, Vacheret H, Habib MC, Devictor B, Lavaut MN, Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res 48: 4368, 1988. 14.Chen C, Bhalala HV, Qiao H, Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21: 6567, 2002. 15.Chen ZY, Shie JL, Tseng CC. Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells. J Biol Chem 277: 46831-46839, 2002. 16.Cho YG, Choi BJ, Song JW, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS. Aberrant expression of krUppel-like factor 6 protein in colorectal cancers. World J Gastroentero 12: 2250, 2006. 17.Chu PY, Hsu NCH, Liao AT, Yeh KT, Hou MF, Liu CH. Elevated Kruppel-like factor 4 transcription factor in canine mammary carcinoma. BMC Vet Res 7: 58, 2011. 18.Dang DT, Pevsner J, Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol 32: 1103-1121, 2000. 19.Destexhe E, Lespagnard L, Degeyter M, Heymann R, Coignoul F. Immunohistochemical identification of myoepithelial, epithelial, and connective tissue cells in canine mammary tumors. Vet Pathol 30: 146-154, 1993. 20.Detre S, Jotti GS, Dowsett M. A' quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878, 1995. 21.Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C. p63 expression profiles in human normal and tumor tissues. Clin Cancr Res 8: 494-501, 2002. 22.Dorn C, Schneider R. Inbreeding and canine mammary cancer: a retrospective study. J Natl Cancer Inst 57: 545, 1976. 23.Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, Van de Vijver M. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Brit J Cancer 88: 406-412, 2003. 24.Fossum TW. Small animal surgery. Mosby-Year Book, Inc., 1997. 25.Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 60: 6488-6495, 2000. 26.Gaglia P, Bernardi A, Venesio T, Caldarola B, Lauro D, Cappa APM, Calderini P, Liscia DS. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 29: 1509-1513, 1993. 27.Gama A, Alves A, Gartner F, Schmitt F. p63: a novel myoepithelial cell marker in canine mammary tissues. Vet Pathol 40: 412-420, 2003. 28.Geraldes M, Gartner F, Schmitt F. Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumours. Vet Rec 146: 403-406, 2000. 29.Gerdes J, Lelle R, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G, Stein H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 39: 977-980, 1986. 30.Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867, 1991. 31.Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, Yang VW. Kruppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res 15: 92-96, 2005. 32.Graham JC, Myers RK. The prognostic significance of angiogenesis in canine mammary tumors. J Vet Intern Med 13: 416-418, 1999. 33.Griffey S, Madewell B, Dairkee S, Hunt J, Naydan D, Higgins R. Immunohistochemical reactivity of basal and luminal epithelium-specific cytokeratin antibodies within normal and neoplastic canine mammary glands. Vet Pathol 30: 155-161, 1993. 34.Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q, Ma D. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 8: 110, 2007. 35.Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 30: 20, 1993. 36.Johnstone A, Thorpe R. Immunochemistry in practice. Blackwell science Cambridge, 1996. 37.Kaczynski J, Cook T, Urrutia R. Sp1-and Kruppel-like transcription factors. Genome Biol 4: 206, 2003. 38.Kaelin Jr WG. The emerging p53 gene family. J Natl Cancer Inst 91: 594-598, 1999. 39.Karayannopoulou M, Kaldrymidou E, Constantinidis T, Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 133: 246-252, 2005. 40.Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116: 823-830, 2001. 41.Lacroix-Triki M, Mery E, Voigt JJ, Istier L, Rochaix P. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34sE12 antibody. Virchows Arch 442: 548-554, 2003. 42.Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol 53: 634-635, 2000. 43.Lelle R, Heidenreich W, Stauch G, Wecke I, Gerdes J. Determination of growth fractions in benign breast disease (BBD) with monoclonal antibody Ki-67. J Cancer Res Clin Oncol 113: 73-77, 1987. 44.Lelle RJ, Heidenreich W, Stauch G, Gerdes J. The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer 59: 83-88, 1987. 45.Leonardi E, Girlando S, Serio G, Mauri F, Perrone G, Scampini S, Dalla Palma P, Barbareschi M. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 45: 416-419, 1992. 46.MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metast Rev 9: 125-136, 1990. 47.MacEwen GE, Harvey JH, Patnaik AK, Mooney S, Hayes A, Kurzman I, Hardy Jr WD. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Immunother 4: 418, 1985. 48.Matsumoto N, Kubo A, Liu H, Akita K, Laub F, Ramirez F, Keller G, Friedman SL. Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357, 2006. 49.Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713, 1999. 50.Misdorp W. Tumors of the mammary gland. Tumors in domestic animals 575-606, 2002. 51.Misdorp W, Else R, Hellmen E, Lipscomb T. Histological classification of mammary tumours of the dog and the cat: Armed Forces Institute of Pathology and American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, International Histological Classification of Tumours of Domestic Animals. 7: 1999. 52.Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G, Cetto GL. Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis. Int J Cancer 74: 433-437, 1997. 53.Mudduwa L, Liyanage T. Immunohistochemical assessment of hormone receptor status of breast carcinoma: Interobserver variation of the quick score. Indian J Med Sci 63: 21, 2009. 54.Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 10: 2709-2719, 2004. 55.Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113: 1099-1105, 1999. 56.Pena L, Dolores Perez-Alenza M, Rodriguez-Bertos A, Nieto A. Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Res Tr 78: 141-148, 2003. 57.Pena LL, Nieto AI, Perez-Alenza D, Cuesta P, Castano M. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 10: 237, 1998. 58.Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M. p63 identifies keratinocyte stem cells. P Natl Acad Sci 98: 3156, 2001. 59.Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegele P, Eber M, Ghnassia JP. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211, 2004. 60.Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW, Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med 17: 102-106, 2003. 61.Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Filipits M. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast cancer ResTr 78: 97-103, 2003. 62.Queiroga F, Perez-Alenza M, Silvan G, Pena L, Lopes C, Illera J. Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol 94: 181-187, 2005. 63.Rao N, Van Wolferen M, Gracanin A, Bhatti S, Krol M, Holstege F, Mol J. Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. J Physiol Pharmacol 60: 73-84, 2009. 64.Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126: 1090-1103, 2004. 65.Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443: 122-132, 2003. 66.Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 127: 336-340, 2003. 67.Roth L. Color Atlas of Veterinary Histology. Vet Clin Path 30: 96-96, 2001. 68.Schneider R. Comparison of age, sex, and incidence rates in human and canine breast cancer. Cancer 26: 419-426, 1970. 69.Simmen R, Pabona J, Velarde M, Simmons C, Rahal O, Simmen F. The emerging role of Kruppel-like factors in endocrine-responsive cancers of female reproductive tissues. J Endodont 204: 223-231, 2010. 70.Simon D, Schoenrock D, Nolte I, Baumgartner W, Barron R, Mischke R. Cytologic examination of fine‐needle aspirates from mammary gland tumors in the dog: diagnostic accuracy with comparison to histopathology and association with postoperative outcome. Vet Clin Path 38: 521-528, 2009. 71.Sims D, Singh A. Cytology and Microscopic Anatomy. Can Vet J 37: 754, 1996. 72.Sorenmo K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 33: 573, 2003. 73.Sorenmo K, Kristiansen V, Cofone M, Shofer F, Breen AM, Langeland M, Mongil C, Grondahl A, Teige J, Goldschmidt M. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol 7: 162-172, 2009. 74.Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 85: 551-556, 2005. 75.Thomson R. Anatomy and physiology of farm animals. Can J Comp Med 45: 334, 1981. 76.Thuroczy J, Reisvaag G, Perge E, Tibold A, Szilagyi J, Balogh L. Immunohistochemical detection of progesterone and cellular proliferation in canine mammary tumours. J Comp Pathol 137: 122-129, 2007. 77.Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A, Leodolter S, Zeillinger R. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res 12: 2442-2448, 2006. 78.Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23: 7212, 2005. 79.van Dierendonck JH, Keijzer R, van de Velde CJH, Cornelisse CJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 49: 2999-3006, 1989. 80.Vos J, Van Den Ingh T, Misdorp W, Molenbeek R, Van Mil F, Rutteman G, Ivanyi D, Ramaekers F. Immunohistochemistry with keratin, vimentin, desmin, and α‐smooth muscle actin monoclonal antibodies in canine mammary gland: Benign mammary tumours and duct ectasias. Vet Quart 15: 89-95, 1993. 81.Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 9: 216-219, 2002. 82.Westfall MD, Pietenpol JA. p63: Molecular complexity in development and cancer. Carcinogenesis 25: 857-864, 2004. 83.Wintzer HO, Zipfel I, Schulte‐Monting J, Hellerich U, von Kleist S. Ki‐67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421-428, 1991. 84.Wrba F, Reiner A, Markis-Ritzinger E, Holzner J, Reiner G, Spona J. Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract 183: 277-283, 1988. 85.Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316, 1998. 86.Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-717, 1999. 87.Zeng Z, Velarde MC, Simmen FA, Simmen RCM. Delayed parturition and altered myometrial progesterone receptor isoform A expression in mice null for Kruppel-like factor 9. Biol Reprod 78: 1029-1037, 2008. 88.Chang CC, Tsai MH, Liao JW, Chan JP, Wong ML, Chang SC. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. J Am Vet Med Assoc 235: 391-396, 2009. 89.Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40: 307-318, 1968. 90.Hampe JF, Misdorp W. Tumours and dysplasias of the mammary gland. Bull World Health Organ 50: 111-133, 1974. 91.Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 43: 1249-1261, 1969. 92.Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res 5: 39, 2009. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65501 | - |
dc.description.abstract | 犬乳腺腫瘤(Canine mammary gland tumors, cMGTs)是雌犬最常發生之腫瘤,其惡性機率從26 %至73 %;目前年齡及卵巢荷爾蒙被認為扮演重要的角色。犬乳腺腫瘤大多延誤治療時機;早期發現且接受正確治療,可避免腫瘤之擴散或轉移。在腫瘤發展進程中,有許多的生物因子可成為惡性腫瘤的生物標記 (Biomarker),因此,針對可能具有潛在的相關生物標記進行研究,以探討是否可以成為生物標記,有其必要性。
本實驗針對176例犬乳腺腫瘤病例作分析,依照WHO犬乳腺腫瘤分類系統與臨床系統分級,配合P63、KLF2、KLF4、KLF5及KLF6等新興蛋白質的表現,結果與Ki-67蛋白質的表現、組織病理學分級及臨床上預後做比較。 初步研究結果發現組織病理學下分類與預後有顯著差異 (P < 0.0001) ,說明正確分類可以達到預測預後之效果。但有時亦混淆的情況下,需要輔助性診斷工具,較常使用的為評估細胞增生因子的Ki-67可以成為區分乳腺腫瘤之良惡性輔助工具;與預後比較,認為大於40 %的Ki-67表現量可以預測其預後較差。Ki-67亦與臨床上分級、組織病理學分類、腫瘤分化與預後皆有顯著相關性。KLF4、KLF5及KLF6在細胞核的表現與惡性腫瘤有相關性,推論這些新興抗體在腫瘤演進過程中,扮演重要角色。將Ki-67與KLF2、KLF4、KLF5及KLF6在細胞核表現情形比較結果皆有非常顯著之相關性 (P < 0.0001)。 | zh_TW |
dc.description.abstract | Canine mammary gland tumors (cMGTs) are the most common neoplasms in intact female dogs and the malignant rate ranges from 41 to 53 %. The most important factors related to cMGTs are age and ovarian hormones. Early detection with subsequent therapies are essential to prevent early local recurrence or distant dissemination. However, these prognostic factors may be not always predictable if a tumor will metastasize or not. The Ki-67, a nuclear antigen, is one of the most commonly used markers to evaluate tumor proliferative activity. In this study, the WHO classification and staging system were used to classify the cMGTs. In addition, the emerging proteins including p63, KLF2, KLF4, KLF5, and KLF6 were employed to compare with histological grading, Ki-67 expression and clinical outcomes.
Current results showed that the histological grading and Ki-67 expression were highly significant associated with clinical outcomes. And the increased 40 % expression of Ki-67 had shorter survival time of patients. Moreover, we suggested that Ki-67 could be used to identify the malignancy and histological grading. Otherwise, the nuclear expression of KLF2, KLF4, KLF5, and KLF6 expression was significantly associated with the malignancy of the cMGTs (P < 0.0001). These emerging proteins, considered the important role in the cancer regulation, also showed significant associated with clinical outcomes through comparison with the expression of Ki-67. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:46:52Z (GMT). No. of bitstreams: 1 ntu-101-R99629015-1.pdf: 6544476 bytes, checksum: 4a2bc06eea222e473007886519acecf9 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii ABSTRACT iii CONTENTS iv LIST OF FIGURES ix LIST OF TABLES x Chapter 1 前言 1 Chapter 2 文獻探討 4 2.1 犬乳腺生理結構 4 2.2 犬乳腺腫瘤 4 2.2.1 犬乳腺腫瘤簡介 4 2.2.2 台灣雌犬之惡性乳腺腫瘤 5 2.2.3 危險因子 6 2.2.4 診斷與分類標準 6 2.2.5 預後因子 7 2.2.6 治療 8 2.3 新興蛋白質與預後之關係 8 2.3.1 Ki-67與乳腺腫瘤及預後之關係 8 2.3.2 P63與乳腺腫瘤及預後之關係 9 2.3.3 Kruppel-like factor 2, 4, 5, 及6與乳腺腫瘤及預後之關係 10 Chapter 3 材料與方法 13 3.1 實驗設計與流程 13 3.2 材料來源 13 3.2.1 基本資料與病史 13 3.3 型態病理學檢查 14 3.3.1 組織病理學檢查 14 3.3.2 免疫組織化學染色 16 3.3.3 評估Ki-67及P63免疫反應 20 3.3.4 評估KLF2, KLF4, KLF5, 及KLF6免疫反應 20 3.4 統計分析 20 Chapter 4 結果 22 4.1 病例臨床數值分析 22 4.2 組織型態病理學分類 23 4.3 乳腺腫瘤組織學分類與存活時間相關性 24 4.4 免疫化學染色評估 24 4.4.1 Ki-67蛋白質表現評估與生存時間相關性 24 4.4.2 Ki-67蛋白質與臨床數值之相關性 25 4.4.3 Ki-67蛋白質在犬乳腺腫瘤表現 26 4.4.4 Ki-67蛋白質與組織學分類間相關性 27 4.4.5 P63蛋白質在犬乳腺腫瘤表現 28 4.4.6 KLF2、4、5及6蛋白質在犬乳腺腫瘤表現 28 4.4.7 Ki-67與KLF2、4、5及6之間之相關性 29 Chapter 5 討論 30 5.1 犬乳腺腫瘤臨床數值與組織學型態分析 30 5.2 犬乳腺腫瘤組織學分類與預後探討 32 5.3 Ki-67與預後之相關 33 5.4 Ki-67與犬乳腺腫瘤臨床數值比較之探討 34 5.5 Ki-67在犬乳腺腫瘤組織病理學分類之表現探討 35 5.6 KLFs在犬乳腺腫瘤之表現探討 37 5.7 Ki-67與KLFs在犬乳腺腫瘤之表現相關性 39 5.8 結論 39 Chapter 6 圖次與表次 41 6.1 表次 41 Table 1: Histological classification of canine mammary tumors. (WHO, 1999) 41 Table 2: cMGTs staging system. 42 Table 3: Source and dilutions of the antibodies used in this study. 43 Table 4: Characteristics of the patients with cMGT. 44 Table 5: Characteristics of the tumor staging and histological classification of the patients with cMGTs. 46 Table 6: Ki-67 percentage among survival. 47 Table 7: Ki-67 > 40 % among survival. 47 Table 8: Ki-67 percentage among location of affected glands. 47 Table 9: Ki-67 > 40 % among location of affected glands. 47 Table 10: Ki-67 percentage among tumor size. 48 Table 11: Ki-67 percentage among stage. 48 Table 12: Ki-67 > 40 % among stage. 48 Table 13: Ki-67 percentage among differentiation. 49 Table 14: Ki-67 > 40 % among differentiation. 49 Table 15: Ki-67 percentage among cMGTs. 49 Table 16: Ki-67 > 40 % among cMGTs. 49 Table 17: Ki-67 percentage among histological classification. 50 Table 18: Ki-67 percentage among different subtypes of cMGTs. 51 Table 19: KLFs expressions in the cMGTs. 53 Table 20: The correlations between the KLFs expressions and Ki-67 percentage. 54 6.2 圖次 55 Figure 1: Kaplan-Meier survival curve: relationship between histological classifications and survival rate in cMGTs. 55 Figure 2 Ki-67 expression correlated with survival. 56 Figure 3: Receiver operating characteristic (ROC) curve: relationship between 40 % of Ki-67 and survival rate. 57 Figure 4 Ki-67 expression correlated with tumor stages. 58 Figure 5: Analysis of variance (ANOVA): relations between Ki-67 and tumor stage. 59 Figure 6 Ki-67 expression correlated with tumor differentiation. 60 Figure 7: Analysis of variance (ANOVA): relations between Ki-67 and tumor differentiation. 61 Figure 8: Immunohistochemical staining of Ki-67 expression in cMGTs. 62 Figure 9 Ki-67 expression correlated with tumor types. 63 Figure 10: Immunohistochemical staining of P63 expression in cMGTs. 64 Figure 11: Immunohistochemical staining of KLFs expression in cMGTs. 65 Chapter 7 參考文獻 66 | |
dc.language.iso | zh-TW | |
dc.title | 犬乳腺腫瘤Ki-67表現與其他新興蛋白質表現之相關性與預後之關係 | zh_TW |
dc.title | The correlations between the prognosis and the expressions of Ki-67 and other emerging proteins in canine mammary gland tumors | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張清棟,廖泰慶,朱旆億 | |
dc.subject.keyword | 犬乳腺腫瘤,組織學分類,免疫化學染色,Ki-67,KLF2,KLF4,KLF5,KLF6, | zh_TW |
dc.subject.keyword | Canine mammary gland tumors (cMGTs),Histological grading,Immunohistochemistry,Ki-67,P63,Kruppel-like factors (KLFs),KLF2,KLF4,KLF5,KLF6, | en |
dc.relation.page | 76 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-07-24 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 6.39 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。